Effects of drug-like molecule promising for development of broad-spectrum antiviral

If researchers were able to activate innate immunity in people, they would be able to control infection in a wide range of viruses, inoculating many against their effects and making them less resistant to drug treatments. Although no broad-spectrum antiviral that would trigger such immunity exists, researchers have identified a molecule that shows promise for creating one, according to a study published in the Journal of Virology.

In tests on cells and mice, RIG-1, the molecule in question, a drug-like compound, was able to induce genes that controlled infections in a range of viruses, including, West Nile, dengue, hepatitis C, Ebola and influenza, among others. This is the first compound shown to trigger innate immunity therapeutically, from a molecule present in every human cell, according to researchers.

When the cellular protein RIG-1 detects viral RNA, it triggers an innate immune response that expresses other antiviral genes and cells, which act together to prevent the virus from taking hold. Should further testing in animal models produce positive results, RIG-1 could be manipulated to produce the equivalent of a broad-spectrum antibiotic for viruses.

More articles on infection control:

Kaiser Permanente bans interior building antimicrobials from its hospitals to curb antibiotic resistance, chemical exposure
Saline water vs. soap: Which is better for cleaning wounds?
WHO publishes list of emerging diseases likely to cause major outbreaks

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers